Merck BOVILIS® 20/20 VISION® 7 WITH SPUR®

Merck BOVILIS® 20/20 VISION® 7 WITH SPUR®

Merck

SKU: SS11421957

$30.00
Unit price per

Options

BOVILIS^® 20/20 VISION^® 7 WITH SPUR^®*

Clostridium Chauvoei-Septicum-Novyi-Sordellii-Perfringens Types C & D-Moraxella Bovis Bacterin-Toxoid

Offers powerful protection against pinkeye, blackleg and more.

Blackleg prevention is critical. But that’s not the only thing calves need protection from. BOVILIS 20/20 VISION 7 WITH SPUR is a comprehensive option that is effective against pinkeye, as well a number of other concerning clostridial diseases. It also contains the proprietary SPUR adjuvant, which results in fewer reactions and reduced stress on cattle post-vaccination.^1-2

Indications

This product has been shown effective for the vaccination of healthy cattle against Clostridium chauvoei, C. septicum, C. novyi, C. sordellii, C. perfringens Type C & D, and Moraxella bovis.

Diseases

Moraxella bovis (Pinkeye)
Clostridium chauvoei (Blackleg)
C. septicum (Malignant edema)
C. novyi (Black disease)
C. sordellii
C. perfringens Types C (Enterotoxemia)
C. perfringens Types D (Enterotoxemia)

The SPUR adjuvant utilized in BOVILIS 20/20 VISION 7 WITH SPUR allows for the highest level of immunization with the lowest level of injection site reactions.^1,2

Dosage

Shake well and administer a single 2 mL dose aseptically by subcutaneous route. Repeat the dose in 3 – 4 weeks. For advice on revaccination frequency, contact your veterinarian.

Preservatives

Contains formaldehyde and polymyxin B as preservatives.

Storage

Store at 2°-8°C (35°-46°F). Do not freeze. Use entire contents when first opened.

Safety

Do not mix with other products. Do not vaccinate within 21 days before slaughter. This product has not been tested in pregnant animals. If allergic reaction occurs, treat with epinephrine. In case of human exposure, contact a physician.
FOR ANIMAL USE ONLY.

Contact

U.S. only: Merck Animal Health livestocktechsrvc@merck-animal-health.com or call 1-800-211-3574
For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov
For additional information, please see the product label.

References

*Adjuvant-Intervet’s Proprietary Technology.
1. Technical Reference 96-4: Evaluation of Injection-Site Blemishes Using Ultrasonography Following Administration of Two Commercial Multivalent Clostridial Vaccines.
2. Technical Reference 96-2: Analysis of Post-Vaccinal Injection Sites Using Ultrasound.